Improving lung cancer treatment through targeted therapies
Official title: Targeting Integrins in Lung Cancer
Funded at VA Northern California Health Care Sys · NIH-10768639 · Data updated 2026-11-12
This study is looking for better ways to help people with advanced lung cancer by creating easy blood tests that can find specific markers in their tumors, so doctors can choose the best treatments and see how well they’re working.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Northern California Health Care Sys NIH-funded |
| Lab location | 1 site (Mather, United States) |
| Project start | February 1, 2021 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| NIH project number | 5I01BX003895-04 |
| Project ID | NIH-10768639 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced non-small cell lung cancer (NSCLC).
✕Less likely to help
Patients with early-stage lung cancer or those with other types of cancer may not receive benefit from this research.
What this research studies
This research focuses on enhancing the treatment of lung cancer by developing new methods to identify and target specific biomarkers in patients. It aims to create sensitive and cost-effective assays that can detect tumor-specific and immune cell-specific markers using simple blood tests. By analyzing biofluid samples from patients with advanced non-small cell lung cancer (NSCLC), the study seeks to improve the selection of appropriate therapies and monitor treatment responses more effectively. The goal is to increase the percentage of patients who benefit from targeted therapies and immunotherapies.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for lung cancer patients by enabling more personalized and effective therapy selection.
How similar studies have gone: Previous research has shown promise in using targeted therapies and biomarker identification in cancer treatment, indicating that this approach could lead to meaningful advancements.
Where this research is happening
-
VA Northern California Health Care Sys
Mather, United States Active
Researchers
- Principal investigator: Li, Tianhong — VA Northern California Health Care Sys
- Study coordinator: Li, Tianhong
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.